1. Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population-based study
- Author
-
Marieke Pape, Pauline A.J. Vissers, Judith de Vos‐Geelen, Maarten C.C.M. Hulshof, Suzanne S. Gisbertz, Paul M. Jeene, Hanneke W.M. van Laarhoven, Rob H.A. Verhoeven, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Internal medicine, APH - Methodology, Surgery, CCA - Cancer Treatment and quality of life, APH - Quality of Care, Graduate School, Oncology, Radiotherapy, CCA - Cancer Treatment and Quality of Life, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism
- Subjects
Male ,Cancer Research ,Esophageal Neoplasms ,palliative treatment ,General Medicine ,Chemoradiotherapy ,NEOADJUVANT CHEMORADIOTHERAPY ,Middle Aged ,Survival Rate ,METASTASES ,Oncology ,distant metastases ,Humans ,Female ,unresectable advanced disease ,Esophageal Squamous Cell Carcinoma ,Registries ,supraclavicular lymph node metastases ,Pneumonectomy ,Aged ,Netherlands ,Retrospective Studies - Abstract
Data on treatment and survival of patients with advanced unresectable esophageal squamous cell carcinoma (ESCC) from Western populations are limited. Here we describe treatment and survival in patients with advanced unresectable ESCC: patients with cT4b disease without metastases (cT4b), metastases limited to the supraclavicular lymph nodes (SCLNM) or distant metastatic ESCC at the population level. All patients with unresectable (cT4b) or synchronous metastatic ESCC at primary diagnosis (2015-2018) or patients with metachronous metastases after primary non-metastatic diagnosis in 2015-2016 were selected from the Netherlands Cancer Registry. Fifteen percent of patients had cT4b disease (n = 146), 12% SCLNM (n = 118) and 72% distant metastases (n = 681). Median overall survival (OS) time was 6.3, 11.2, and 4.4 months in patients with cT4b, SCLNM, and distant metastases, respectively (P
- Published
- 2021
- Full Text
- View/download PDF